666 related articles for article (PubMed ID: 24561444)
1. RET revisited: expanding the oncogenic portfolio.
Mulligan LM
Nat Rev Cancer; 2014 Mar; 14(3):173-86. PubMed ID: 24561444
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.
Plaza-Menacho I; Mologni L; McDonald NQ
Cell Signal; 2014 Aug; 26(8):1743-52. PubMed ID: 24705026
[TBL] [Abstract][Full Text] [Related]
3. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
[TBL] [Abstract][Full Text] [Related]
4. Central role of RET in thyroid cancer.
Santoro M; Carlomagno F
Cold Spring Harb Perspect Biol; 2013 Dec; 5(12):a009233. PubMed ID: 24296167
[TBL] [Abstract][Full Text] [Related]
5. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
6. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
[TBL] [Abstract][Full Text] [Related]
8. 65 YEARS OF THE DOUBLE HELIX: Exploiting insights on the RET receptor for personalized cancer medicine.
Mulligan LM
Endocr Relat Cancer; 2018 Aug; 25(8):T189-T200. PubMed ID: 29743166
[TBL] [Abstract][Full Text] [Related]
9. RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer.
Mahato AK; Sidorova YA
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32993133
[TBL] [Abstract][Full Text] [Related]
10. REToma: a cancer subtype with a shared driver oncogene.
Kohno T; Tabata J; Nakaoku T
Carcinogenesis; 2020 Apr; 41(2):123-129. PubMed ID: 31711124
[TBL] [Abstract][Full Text] [Related]
11. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
Lodish MB; Stratakis CA
Expert Rev Anticancer Ther; 2008 Apr; 8(4):625-32. PubMed ID: 18402529
[TBL] [Abstract][Full Text] [Related]
12. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.
Kodama Y; Asai N; Kawai K; Jijiwa M; Murakumo Y; Ichihara M; Takahashi M
Cancer Sci; 2005 Mar; 96(3):143-8. PubMed ID: 15771616
[TBL] [Abstract][Full Text] [Related]
13. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.
de Groot JW; Links TP; Plukker JT; Lips CJ; Hofstra RM
Endocr Rev; 2006 Aug; 27(5):535-60. PubMed ID: 16849421
[TBL] [Abstract][Full Text] [Related]
14. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC).
Kim DW; Chung HK; Park KC; Hwang JH; Jo YS; Chung J; Kalvakolanu DV; Resta N; Shong M
Mol Endocrinol; 2007 Dec; 21(12):3039-49. PubMed ID: 17761947
[TBL] [Abstract][Full Text] [Related]
15. Development of RET kinase inhibitors for targeted cancer therapy.
Mologni L
Curr Med Chem; 2011; 18(2):162-75. PubMed ID: 21110809
[TBL] [Abstract][Full Text] [Related]
16. Differential roles of RET isoforms in medullary and papillary thyroid carcinomas.
Lian EY; Maritan SM; Cockburn JG; Kasaian K; Crupi MJ; Hurlbut D; Jones SJ; Wiseman SM; Mulligan LM
Endocr Relat Cancer; 2017 Jan; 24(1):53-69. PubMed ID: 27872141
[TBL] [Abstract][Full Text] [Related]
17. The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.
Iervolino A; Iuliano R; Trapasso F; Viglietto G; Melillo RM; Carlomagno F; Santoro M; Fusco A
Cancer Res; 2006 Jun; 66(12):6280-7. PubMed ID: 16778204
[TBL] [Abstract][Full Text] [Related]
18. RET inhibition: implications in cancer therapy.
Borrello MG; Ardini E; Locati LD; Greco A; Licitra L; Pierotti MA
Expert Opin Ther Targets; 2013 Apr; 17(4):403-19. PubMed ID: 23461584
[TBL] [Abstract][Full Text] [Related]
19. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
20. Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations.
Kjaer S; Kurokawa K; Perrinjaquet M; Abrescia C; Ibáñez CF
Oncogene; 2006 Nov; 25(53):7086-95. PubMed ID: 16732321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
